Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7532745 | 0.88 | MAPK1 (0.48) | SMN1; SMN2LMNAKMT2AGABRA1GABRG2 | |
| SCHEMBL8159500 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAKMT2AGABRA1GABRG2 | |
| SCHEMBL20206259 | 0.77 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAKMT2AGABRA1GABRG2 | |
| SCHEMBL2090662 | 0.76 | L3MBTL1 (0.55) | KMT2AGABRA1GABRG2GABRB3CA1 | |
| SCHEMBL7567234 | 0.76 | FABP4 (0.45) | SMN1; SMN2GABRA1GABRB1GABRB2SOAT2 | |
| SCHEMBL812723 | 0.75 | GABRA1 (0.52) | SMN1; SMN2LMNAKMT2AGABRA1GABRG2 | |
| SCHEMBL3244890 | 0.75 | L3MBTL1 (0.42) | SMN1; SMN2LMNAKMT2AGABRA1GABRG2 | |
| SCHEMBL23849483 | 0.74 | GABRA1 (0.48) | SMN1; SMN2LMNAGABRA1GABRB1LPAR1 | |
| SCHEMBL6180997 | 0.73 | GABRA1 (0.50) | SMN1; SMN2LMNAKMT2AGABRA1GABRG2 | |
| SCHEMBL429149 | 0.71 | ALDH1A1 (0.39) | SMN1; SMN2LMNAKMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| US-5502198-A | α-aryl or heteroaryl-substituted amide ester ACAT inhibitors | WARNER-LAMBERT COMPANY (US) | 1996-03-26 | — | — | US | claimed |
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | CORNICELLI JOSEPH ANTHONY (US) | 2002-12-05 | — | — | US | disclosed |
| EP-1236468-A1 | Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | disclosed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | disclosed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | disclosed |
| US-6017905-A | TREATMENT OF HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 2000-01-25 | — | — | US | disclosed |
| US-5807846-A | TREATING HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1998-09-15 | — | — | US | disclosed |
| EP-0730571-A1 | ALPHA-ARYL OR HETEROARYL-SUBSTITUTED AMIDE ESTER ACAT INHIBITORS | PARKE, DAVIS & COMPANY (US) | 1996-09-11 | — | — | EP | disclosed |
| US-5502198-A | α-aryl or heteroaryl-substituted amide ester ACAT inhibitors | WARNER-LAMBERT COMPANY (US) | 1996-03-26 | — | — | US | disclosed |
| US-5208224-A | Phosphorus containing compounds as antihypercholesterolemic and antiatherosclerotic agents | WARNER-LAMBERT COMPANY (US) | 1993-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183384-A1 | Methods of treating nuclear factor-kappa B mediated diseases and disorders | NFKBIA, IKBKB, RELA | SMN1; SMN2 671/4885LMNA 2706/4885KMT2A 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.